Intellia Therapeutics Inc (NASDAQ:NTLA) was down 1.1% during trading on Tuesday . The stock traded as low as $19.55 and last traded at $19.71, with a volume of 82,970 shares trading hands. The stock had previously closed at $19.93.

Several equities research analysts have commented on NTLA shares. Leerink Swann started coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 price objective for the company. Credit Suisse Group AG started coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 price objective for the company. Jefferies Group started coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They issued a “hold” rating and a $33.00 price objective for the company. Finally, Wedbush started coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They issued an “outperform” rating and a $38.00 price objective for the company.

The stock has a 50 day moving average of $25.32 and a 200 day moving average of $25.42. The company’s market capitalization is $670.61 million.

In other Intellia Therapeutics news, Director Carl L. Gordon acquired 250,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average price of $18.00 per share, with a total value of $4,500,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Bros. Advisors Lp Baker acquired 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $3,600,000.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.